drugset / Trial / NCT06155578

Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis

NCT06155578 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This prospective placebo-controlled trial will enroll 20 patients with SSc and at least one calcinotic lesion of the hands that is palpable on physical examination and measurable on hand radiographs. Each subject will undergo a screening evaluation 1 month before treatment with the study drug is initiated. Each subject will be instructed to blindly self-apply either topical 25% sodium metabisulfite or placebo cream twice daily. In-person follow-up evaluations will be performed after 4-months, with monthly telehealth follow-up visits to ensure adherence and arrange study drug refill deliveries.

Timeline

Start
2024-01-02
Primary completion
2024-12-31
Completion
2024-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator METASULFUROUS ACID Small molecule 25 % Topical